AtriCure, Inc. (NASDAQ:ATRC) Receives $52.44 Consensus PT from Brokerages

AtriCure, Inc. (NASDAQ:ATRC) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $52.4444.

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of AtriCure from $42.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Finally, Canaccord Genuity Group boosted their price target on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 30th.

Insider Activity at AtriCure

In related news, insider Justin J. Noznesky sold 5,166 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $37.29, for a total transaction of $192,640.14. Following the completion of the sale, the insider owned 78,798 shares in the company, valued at $2,938,377.42. The trade was a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Maggie Yuen sold 3,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $35.72, for a total value of $107,160.00. Following the completion of the sale, the director directly owned 11,371 shares of the company’s stock, valued at approximately $406,172.12. This trade represents a 20.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 18,166 shares of company stock valued at $676,378. 3.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On AtriCure

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRC. Ameritas Investment Partners Inc. grew its stake in shares of AtriCure by 6.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,941 shares of the medical device company’s stock worth $162,000 after purchasing an additional 312 shares during the period. PNC Financial Services Group Inc. grew its position in shares of AtriCure by 6.5% during the third quarter. PNC Financial Services Group Inc. now owns 6,188 shares of the medical device company’s stock worth $218,000 after buying an additional 380 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in AtriCure by 5.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock worth $246,000 after acquiring an additional 385 shares in the last quarter. Scotia Capital Inc. grew its stake in shares of AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after purchasing an additional 457 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd increased its stake in AtriCure by 197.1% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock valued at $29,000 after buying an additional 538 shares during the period. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Trading Down 0.5%

ATRC stock opened at $40.33 on Thursday. The company has a quick ratio of 2.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -66.11 and a beta of 1.47. AtriCure has a twelve month low of $28.29 and a twelve month high of $43.11. The firm’s fifty day simple moving average is $36.81 and its two-hundred day simple moving average is $35.16.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. The firm had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative return on equity of 2.54% and a negative net margin of 5.55%.AtriCure’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. As a group, analysts anticipate that AtriCure will post -0.6 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.